Detalhe da pesquisa
1.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Blood
; 143(13): 1242-1258, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096363
2.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Blood
; 141(14): 1724-1736, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36603186
3.
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Blood
; 142(18): 1543-1555, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37562004
4.
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood
; 137(9): 1192-1195, 2021 03 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33080624
5.
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Hematol Oncol
; 38(4): 446-455, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32472610
6.
Prognostic role of circulating exosomal miRNAs in multiple myeloma.
Blood
; 129(17): 2429-2436, 2017 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28213378
7.
The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.
BMC Cancer
; 19(1): 855, 2019 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31464608
8.
Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
Clin Chem Lab Med
; 57(9): 1397-1405, 2019 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30973821
9.
Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Blood
; 125(13): 2095-100, 2015 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25636340
10.
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Blood
; 126(25): 2713-9, 2015 Dec 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26516228
11.
Differential and limited expression of mutant alleles in multiple myeloma.
Blood
; 124(20): 3110-7, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25237203
12.
Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications.
Blood Adv
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513088
13.
The shaping and functional consequences of the dosage effect landscape in multiple myeloma.
BMC Genomics
; 14: 672, 2013 Oct 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24088394
14.
Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma.
Br J Haematol
; 163(3): 343-51, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24032635
15.
Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.
Blood
; 118(3): 675-8, 2011 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-21628407
16.
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Blood
; 117(6): 2009-11, 2011 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20962323
17.
Exploring the impact of dexamethasone on gene regulation in myeloma cells.
Life Sci Alliance
; 6(9)2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524526
18.
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.
Nat Cancer
; 4(11): 1536-1543, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37653140
19.
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.
Blood
; 2010 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20962322
20.
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
Blood Cancer J
; 12(12): 171, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535935